CKMH Overweight / Obesity
There is no content available at this time. Please check again later.
Relevant Content
Associations of Cardiovascular–Kidney–Metabolic Syndrome With All‐Cause and Cardiovascular Death and the Progression of Cardiovascular–Kidney–Metabolic Syndrome Among Hong Kong Chinese People Over 2 Decades
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy
Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance
Journal of the American Heart Association, Ahead of Print.
Background...
Methodologic Standards for Follow-Up Extension in Cardiovascular Trials
Background...
Extension follow-up studies address long-term questions beyond the parent...
Comprehensive Clinical Approach to Cardiovascular Kidney Metabolic Syndrome
Polypharmacy is common in cardiovascular (CV) care because guideline-direc...
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Circulation, Volume 154, Issue 1, Page 66-73, July 7, 2026.
GLP-1 (gl...
Researchers at Heart
GLP-1 (gl...
Circulation: Population Health and Outcomes, Ahead of Print.
BACKGROU...
Strategies for Optimizing Heart Failure Care in the Older Adult
BACKGROU...
Heart failure (HF) in older adults is a growing and distinct clinical chal...
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
Guideline offering updated evidence on cardiovascular‑kidney‑metabolic syn...
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease
The American Heart Association Predicting Risk of Cardiovascular Disease E...